| Jun 14 |
Shattuck (STTK) Announces Positive Interim Data on Cancer Drug
|
| Jun 14 |
Shattuck gains on early-stage data update for lead asset in blood cancer
|
| Jun 14 |
Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid L...
|
| Jun 10 |
Shattuck gets FDA orphan drug designation for SL-172154 for AML
|
| Jun 10 |
Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML)
|
| Jun 1 |
Most Shareholders Will Probably Agree With Shattuck Labs, Inc.'s (NASDAQ:STTK) CEO Compensation
|
| May 21 |
After Plunging -19.89% in 4 Weeks, Here's Why the Trend Might Reverse for Shattuck Labs (STTK)
|
| May 14 |
Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at th...
|
| May 7 |
What Makes Shattuck Labs (STTK) a New Buy Stock
|
| May 7 |
Does Shattuck Labs (STTK) Have the Potential to Rally 34.17% as Wall Street Analysts Expect?
|
